Approval · Notice of Compliance 32882 · 2024
PREVYMIS: Notice of Compliance 32882
Issued March 13, 2024
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 32882
- Date
- March 13, 2024
- Company
- Merck Canada IncKirkland, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- To provide an option to extend the prophylaxis of cytomegalovirus (CMV) infection in allogeneic hematopoietic stem cell transplant (HSCT) patients.
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| PREVYMIS | Not yet assigned | — |
Medicinal ingredients
- LETERMOVIR 240 MG per TAB
- LETERMOVIR 480 MG per TAB
- LETERMOVIR 240 MG per 12ML
- LETERMOVIR 480 MG per 24ML